Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Buy” by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month […]
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month […]
